Patents by Inventor Jonathan VIGNE

Jonathan VIGNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION
    Publication number: 20210347890
    Abstract: Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
    Type: Application
    Filed: July 19, 2021
    Publication date: November 11, 2021
    Inventors: Sylvie BAY, Antonino NICOLETTI, Dominique LE GULUDEC, Jonathan VIGNE, Giuseppina CALIGIURI
  • CD31 as a molecular target for imaging of inflammation
    Patent number: 11098124
    Abstract: Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: August 24, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Sylvie Bay, Antonino Nicoletti, Dominique Le Guludec, Jonathan Vigne, Giuseppina Caligiuri
  • CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION
    Publication number: 20190092858
    Abstract: Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 28, 2019
    Inventors: Sylvie BAY, Antonino NICOLETTI, Dominique LE GULUDEC, Jonathan VIGNE, Giuseppina CALIGIURI